Get the Stockscreener App
125.61
6.26%
7.40
After Hours:
124.00
-1.61
-1.28%
Repligen Corp stock is traded at $125.61, with a volume of 2.09M.
It is up +6.26% in the last 24 hours and up +6.65% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$118.21
Open:
$121.24
24h Volume:
2.09M
Relative Volume:
2.20
Market Cap:
$7.08B
Revenue:
$738.26M
Net Income/Loss:
$48.89M
P/E Ratio:
145.30
EPS:
0.8645
Net Cash Flow:
$91.69M
1W Performance:
+6.97%
1M Performance:
+6.65%
6M Performance:
-13.87%
1Y Performance:
-10.86%
1-Day Range:
$120.62
$128.31
1-Week Range:
$110.58
$128.31
52-Week Range:
$109.50
$175.77
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
125.61 | 6.67B | 738.26M | 48.89M | 91.69M | 0.8645 |
ISRG
Intuitive Surgical Inc
|
451.38 | 160.21B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.17 | 41.62B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
45.32 | 37.37B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
74.45 | 35.82B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
207.88 | 30.38B | 5.40B | 1.49B | 1.78B | 10.12 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-01-25 | Initiated | HSBC Securities | Buy |
| Sep-22-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
Repligen (RGEN) Shares Skyrocket, What You Need To Know - FinancialContent
Repligen Corp (NASDAQ:RGEN) Sees Pre-Market Gain After Q1 Earnings Beat Offsets Slight Revenue Miss - ChartMill
Repligen’s (NASDAQ:RGEN) Q1 CY2026 Sales Beat Estimates - FinancialContent
Repligen: Q1 Earnings Snapshot - KTVB
Repligen (NASDAQ: RGEN) posts 15% Q1 revenue growth and lifts 2026 EPS view - Stock Titan
Repligen raises 2026 profit target after $194M first quarter - Stock Titan
Repligen Corporation $RGEN Shares Sold by Vanguard Group Inc. - MarketBeat
Repligen Corporation $RGEN Holdings Raised by Artemis Investment Management LLP - MarketBeat
Repligen Corporation (NASDAQ:RGEN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Conestoga Capital Advisors LLC Buys 101,062 Shares of Repligen Corporation $RGEN - MarketBeat
RGEN SEC FilingsRepligen 10-K, 10-Q, 8-K Forms - Stock Titan
Delta Investment Management LLC Reduces Stake in Repligen Corporation $RGEN - MarketBeat
Is Repligen Corp (RGEN) a Bargain After 3.7% Drop? GF Value Says Undervalued - GuruFocus
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Tempered Forward Expectations Hurt Repligen Corp. (RGEN) in Q1 - Yahoo Finance
Impax Asset Management Group plc Sells 289,853 Shares of Repligen Corporation $RGEN - MarketBeat
A Look at Repligen Corp (RGEN) After 3.1% Gain -- GF Value $173. - GuruFocus
Repligen slides 8.3% as CEO share sale disclosure weighs on sentiment - Quiver Quantitative
Repligen Corporation stock hits 52-week low at 109.66 USD - Investing.com
Repligen Corporation stock hits 52-week low at 109.66 USD By Investing.com - Investing.com Canada
M&T Bank Corp Purchases New Holdings in Repligen Corporation $RGEN - MarketBeat
Why Repligen (RGEN) Shares Are Plunging Today - Yahoo Finance
Repligen Corp (RGEN) Stock Down 6.2% -- Now Undervalued? GF Scor - GuruFocus
Insider Sell: Olivier Loeillot Sells Shares of Repligen Corp (RG - GuruFocus
Repligen CEO Loeillot sells $536,480 in company stock By Investing.com - Investing.com India
Repligen CEO Loeillot sells $536,480 in company stock - Investing.com
Repligen Corp (RGEN) CEO sells 3,832 shares under 10b5-1 plan - Stock Titan
Repligen to Report First Quarter 2026 Financial Results - ChartMill
Assessing Repligen (RGEN) Valuation After Recent Share Price Rebound - Yahoo Finance
Goldman Sachs (GSCE) priced capped notes linked to Repligen (RGEN) stock - Stock Titan
[144] REPLIGEN CORP SEC Filing - Stock Titan
Here’s What Positioned Repligen Corporation (RGEN) for a Durable Long-Term Growth - Insider Monkey
Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen Stocks Trade Up, What You Need To Know - Yahoo Finance
Repligen Corp stock (US7607591002): Is its bioprocessing dominance strong enough to unlock new upsid - AD HOC NEWS
Repligen opens third training center in Netherlands facility By Investing.com - Investing.com South Africa
Repligen opens third training center in Netherlands facility - Investing.com
Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network - ChartMill
Rothschild Redburn initiates Repligen stock with buy on bioprocessing strength By Investing.com - Investing.com South Africa
Rothschild Redburn initiates Repligen stock with buy on bioprocessing strength - Investing.com Australia
Repligen Corp (RGEN) Shares Fall 3.7% -- What GF Score of 85 Tel - GuruFocus
Short Interest in Repligen Corporation (NASDAQ:RGEN) Rises By 28.0% - MarketBeat
Repligen Corp (RGEN) Stock Up 6.9% and Still Undervalued -- GF S - GuruFocus
Repligen Corp stock (US7607591002): Is bioprocessing demand strong enough to unlock new upside? - AD HOC NEWS
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
RGEN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analyst Lowers Price Target for RGEN Amid Continued Outperform R - GuruFocus
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance Australia
Repligen (RGEN) Valuation Check After Mixed Share Price Returns And High P/E Multiple - Yahoo Finance
Repligen Corp (RGN.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Repligen Corp at Leerink Global Healthcare Conference Transcript - GuruFocus
Repligen (NASDAQ: RGEN) details 2025 growth, CEO pay and governance in 2026 proxy - stocktitan.net
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):